The PURE study team, with MyLinh Duong as first author, has published the article, Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study, in THE LANCET Global Health journal.
The article notes that “there is little data on whether mild abnormalities in lung function, within clinically normal range, are associated with similar increases in poor health outcomes. Furthermore, most evidence is from western populations in high-income countries, whereas less data and knowledge are available regarding these associations in middle-income and low-income countries, where the scope of risk exposures, population susceptibility, and aetiological factors for lung function impairment are different.”
In the prospective cohort study, PURE, involving 126,359 adults from 628 urban and rural communities across 17 high-income, middle-income, and low-income countries, the PHRI-led team of researchers observed significant and graded increases in rates and risks of mortality, cardiovascular disease events, and respiratory hospitalizations with decreasing FEV1 values standardized by country-specific values (FEV1%).
The paper concludes “we showed a significant and graded relationship between lower baseline country-standardized FEV1% and future risk of mortality and cardio-respiratory morbidity. Addressing mild reductions in lung function could have a substantial effect on the population burden of cardio-respiratory diseases, particularly in high-risk groups such as tobacco users, people with known cardiovascular disease, and those living in poorly resourced settings. Further studies are also needed to examine how routine lung function measurement can help to better inform on the overall risk for poor general health outcomes.”